KYMR - Kymera Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

KYMR is currently covered by 16 analysts with an average price target of $43.46. This is a potential upside of $10.2 (30.67%) from yesterday's end of day stock price of $33.26.

Kymera Therapeutics's activity chart (see below) currently has 61 price targets and 84 ratings on display. The stock rating distribution of KYMR is 36.73% HOLD and 63.27% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 69.19% with an average time for these price targets to be met of 242.8 days.

Highest price target for KYMR is $74, Lowest price target is $41, average price target is $51.71.

Most recent stock forecast was given by GEOFF MEACHAM from CITI on 13-Mar-2025. First documented stock forecast 15-Sep-2020.

Currently out of the existing stock ratings of KYMR, 18 are a HOLD (36.73%), 31 are a BUY (63.27%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$52

$18.74 (56.34%)

$43

1 months 14 days ago
(13-Mar-2025)

4/6 (66.67%)

$18.55 (55.46%)

90

Buy

$60

$26.74 (80.40%)

$46

1 months 30 days ago
(28-Feb-2025)

5/8 (62.5%)

$28.65 (91.39%)

45

Buy

$57

$23.74 (71.38%)

$38

4 months 25 days ago
(02-Dec-2024)

6/8 (75%)

$9.26 (19.40%)

169

Hold

$49

$15.74 (47.32%)

$45

5 months 21 days ago
(06-Nov-2024)

5/5 (100%)

$-0.48 (-0.97%)

100

Buy

$74

$40.74 (122.49%)

$80

5 months 23 days ago
(04-Nov-2024)

0/2 (0%)

$26.93 (57.21%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is KYMR (Kymera Therapeutics) average time for price targets to be met?

On average it took 242.8 days on average for the stock forecasts to be realized with a an average price target met ratio 69.19

Which analyst has the current highest performing score on KYMR (Kymera Therapeutics) with a proven track record?

EDWARD TENTHOFF

Which analyst has the most public recommendations on KYMR (Kymera Therapeutics)?

Edward Tenthoff works at PIPER SANDLER and has 5 price targets and 4 ratings on KYMR

Which analyst is the currently most bullish on KYMR (Kymera Therapeutics)?

Eliana Merle with highest potential upside - $40.74

Which analyst is the currently most reserved on KYMR (Kymera Therapeutics)?

Vikram Purohit with lowest potential downside - $0.74

Kymera Therapeutics in the News

Kymera Therapeutics Appoints Noah Goodman as Chief Business Officer

WATERTOWN, Mass., April 09, 2025 (GLOBE NEWSWIRE) — Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Noah Goodman, M.B.A., as Chief Business Officer. Mr. Goodman brings a wealth of diverse experience in the life sciences industry...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?